تا بعدی

پخش خودکار

Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS

1 بازدیدها • 07/16/23
اشتراک گذاری
جاسازی کنید
administrator
administrator
مشترکین
0

Visit http://www.ecancer.org for more

Prof Margolese (The Jewish General Hospital, McGill University, Montreal, Canada) talks to ecancertv at ASCO 2015 about a federally funded phase III trial that suggests postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.

بیشتر نشان بده، اطلاعات بیشتر
0 نظرات sort مرتب سازی بر اساس
نظرات فیس بوک

تا بعدی

پخش خودکار